Sanofi SA Inhaber EO 2

€ 77,34 <%= Resources.Global.txtUp %>

Opdateret 20:58:18
ISIN: FR0000120578

I dag

Market closed

Marked er lukket, åbner klokken 09:00

	14:01	Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

	22 jul	Sanofi : Information concerning the total number of voting rights and shares

	11 jul	Sanofi : First Ever Dengue Vaccine Candidate To Show Efficacy Against Dengue Fever and Dengue Haemorrhagic Fever in Asia

	09 jul	Sanofi :Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

	08 jul	FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo®

	04 jul	Sanofi : Pre-quarterly Results Communication

	23 jun	SANOFI : Information concerning the total number of voting rights and shares

	14 jun	Sanofi Reports Positive Phase 3 Results for Toujeo®

	14 jun	Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes

	12 jun	Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR:

For lav Flash Player version